{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-24-000046","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.614073+00:00","generated_at":"2026-05-31T05:51:40.132893+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xencor unveils autoimmune pipeline, reports initial XmAb819 RECIST responses in ccRCC","bullets":["XmAb942 (anti-TL1A) Phase 1 healthy volunteer study starts Q4 2024; interim data in H1 2025.","Plamotamab (CD20xCD3) Phase 1b/2a in multi-drug resistant RA to begin H1 2025.","XmAb657 (CD19xCD3) Phase 1 in autoimmune disease starts H2 2025; preclinical B-cell depletion >99.98%.","XmAb819 (ENPP3xCD3) shows RECIST responses in ccRCC; dose escalation continues, target dose by YE 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-24-000046","json":"https://secwatch.observer/filing/0001326732-24-000046.json","markdown":"https://secwatch.observer/filing/0001326732-24-000046.md","text":"https://secwatch.observer/filing/0001326732-24-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000046/0001326732-24-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000046/xncr-20240909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:51:40.132893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}